SC: Absence of Independent Witnesses is Not Fatal if Injured Eyewitness Testimony is Sterling || Supreme Court: Prosthetic Limb Costs Must Be Compensated To Restore Victims’ Dignity || Supreme Court: Probate Can be Revoked For Non-Impleadment of Parties and Suppression of Facts || SC: Plaint Cannot be Rejected For Valuation or Court Fee Defects Without Chance to Rectify || SC Rules Government Grants Act Overrides Rent Law, Sets Aside Eviction Proceeding Against Union Govt || SC: Civil Court Has No Jurisdiction in Boundary Dispute Between Maharashtra Panchayat & Municipality || Allahabad HC: Two Criminal Cases Insufficient to Label a Person as 'Goonda' and Harm Reputation || Bom HC: Sprinkling Mustard Without Ill Intent Before a House is Not an Offence under Black Magic Act || J&K&L HC: Preventive Detention Invalid When Based on Speculative Fear of Election Disturbance || Bombay High Court: POSH Act Penalises False Complaints by Women But Not Those Who Instigate Them

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :